Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Chemotherapy for Cervical Cancer (CIMAHOPE)
NCT03413579Phase 3Completed
- Sponsor
- El Kendi
- Start
- Nov 2015
- Primary completion
- Mar 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in Cervical Cancer (CC), sponsored by El Kendi. Started Nov 2015; status: completed.
02
Drugs
nimotuzumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03413579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03413579.